...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Microencapsulation: Microcapsules Liposomes Nanoparticles Microcells Microspheres >Poly(D,L-lactide-co-glycolide)microspheres for long-term intravitrealdelivery of aciclovir:influence of fatty and non-fatty additives
【24h】

Poly(D,L-lactide-co-glycolide)microspheres for long-term intravitrealdelivery of aciclovir:influence of fatty and non-fatty additives

机译：聚（D，L-丙交酯-共-乙交酯）微球用于玻璃体内阿昔洛韦的长期递送：脂肪和非脂肪添加剂的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aciclovir (acicloguanosine)has been demonstrated to be effective in the treatment of intraocular pathologies such as herpes simplex virus retinitis and acute retinal necrosis.Although intravitreal injections have been used with fewer side-effects than intravenous administration,the risk of complications increases with the frequency of intravitreous injections.For this reason,a biodegradable drug-delivery system,such as microspheres,able to promote prolonged release of the drug,offers a good alternative to multiple intraocular administrations.In this work,aciclovir-containing poly (D,L-lactide-co-glycolide)microspheres were prepared by the solvent evaporation method.Seven additives were incorporated in the microspheres to modulate the in vitro release rate of the drug: four non-fatty substances (polyethylene glycol 300,polyethylene glycol 1500,hidroxypropyl methylcellulose and gelatin)and three fatty substances (isopropyl myristate,vitamin E and Labrafil M 1944 CS).Morphology of microspheres was evaluated by scanning electron microscopy.Granulometric analysis showed that particle size distribution was significantly influenced by the incorporation of additives.Loading efficiency decreased when fatty substances were added,whereas non-fatty additives promoted higher incorporation of the drug.Infrared and differential scanning calorimetry analyses indicated that microspheres prepared by the solvent evaporation process were not influenced by the type of additive used.In all cases,the initial burst resulted less than 5%.Additive-free microspheres showed a slow release within the first days,but when additives were incorporated,in general,the release rates of the drug were increased.Best release results were obtained for gelatin-containing microspheres.The release of aciclovir from these microspheres was adjusted to a zero-order kinetic from 1 to 49 days with a release constant of 1.13 mug/day/mg microspheres.A dose of 0.74mg microspheres would be therapeutic for the herpes simplex and Epstein-Barr viruses (MIC 0.1 mug/ml)and 7.4mg for varicella zoster virus (MIC 1 mug/ml)treatment in an animal model.
机译：已证明阿昔洛韦（acicloguanosine）可有效治疗眼内病变，例如单纯疱疹病毒性视网膜炎和急性视网膜坏死。尽管玻璃体内注射的副作用少于静脉注射，但并发症发生的风险随频率的增加而增加因此，可生物降解的药物传递系统（如微球）可以促进药物的长时间释放，是多次眼内给药的良好选择。在这项工作中，含阿昔洛韦的聚（D，L-通过溶剂蒸发法制备丙交酯-乙交酯共聚物微球，在微球中掺入七种添加剂以调节药物的体外释放速率：四种非脂肪物质（聚乙二醇300，聚乙二醇1500，羟丙基甲基纤维素和明胶）和三种脂肪物质（肉豆蔻酸异丙酯，维生素E和Labrafil M 1944 CS）。粒度分析表明，添加剂的加入对粒度分布有显着影响。添加脂肪物质后装填效率下降，而非脂肪添加剂促进了药物的更高掺入。红外和差示扫描量热法分析表明，溶剂蒸发法制得的微球不受所用添加剂的类型的影响。在所有情况下，最初的爆破结果均小于5％。无添加剂的微球在头几天内释放缓慢，但当添加剂为含明胶的微球获得了最佳的释放结果。阿昔洛韦从这些微球的释放调整为零级动力学，时间为1至49天，释放常数为1.13杯/天/毫克微球。0.74毫克微球的剂量可治疗疱疹在动物模型中治疗单纯性和爱泼斯坦-巴尔病毒（MIC 0.1杯/毫升）和7.4毫克水痘带状疱疹病毒（MIC 1杯/毫升）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号